Latham & Watkins Advises atai Life Sciences on Combination with Beckley Psytech to Form AtaiBeckley

Latham & Watkins LLP represented atai Life Sciences in the strategic combination with Beckley Psytech Limited that formed AtaiBeckley (Atai Beckley N.V.). Atai Beckley N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on developing rapid-acting and convenient mental health treatments, has announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech Limited. The transaction was effected as an all-share combination and brings together scientific and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens aimed at addressing significant unmet needs in mental health. Latham & Watkins LLP represented client(s) atai Life Sciences in the transaction with a team composed by: Nathan Ajiashvili (New York partner, corporate); Robbie McLaren (London partner, corporate); Scott Shean (Orange County partner, corporate); Brian Umanoff (Orange County partner, corporate); Samantha Peacock (associate, corporate); Abby Timmons (associate, corporate); Richard Dodding (associate, corporate); Kaj Nielsen (associate, corporate); Christopher Siino (associate, corporate); Adam Picker (associate, corporate); Elana Cates (associate, corporate); Chloe Barr (associate, corporate). Advice on executive compensation and employee benefits was provided by Sarah Gadd (London partner, executive compensation and employee benefits), David Della Rocca (Washington, D.C. partner, executive compensation and employee benefits) and Venice Ma (associate, executive compensation and employee benefits). Public company matters were handled by Irina Yevmenenko (New York counsel, public company matters) with associate Catriela Cohen (public company matters).

Latham & Watkins Advises atai Life Sciences on Combination with Beckley Psytech to Form AtaiBeckley

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads